Afrigen Biologics Receives $6.2 Million Grant to Develop mRNA Rift Valley Fever Vaccine
Key Insights
Afrigen Biologics (search) secures a $6.2 million grant from CEPI to develop an mRNA vaccine against Rift Valley fever (search), addressing a critical unmet need.
The collaboration with the International Vaccine Institute aims to advance the vaccine candidate through preclinical studies and Phase I clinical trials in Africa.
The new vaccine seeks to combat the potentially deadly Rift Valley fever (search), which poses significant risks to both human health and livestock.
Afrigen Biologics (search) has been awarded a $6.2 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop the first mRNA-based vaccine against Rift Valley fever (search) (RVF). This initiative aims to address the urgent need for a human vaccine against the disease, which poses a significant threat to both human and animal health, particularly in Africa.
The project will involve collaboration with the International Vaccine Institute to advance the new vaccine candidate through preclinical development and into Phase I clinical testing. The trials are planned to take place in either South Africa or another outbreak-affected country on the African continent.
The Need for a Rift Valley Fever Vaccine
Rift Valley fever (search), first identified in Kenya in the 1930s, is typically contracted through direct contact with infected animals such as sheep, goats, and cattle, or through the bites of infected mosquitoes, according to the U.S. CDC. While most infected individuals experience mild symptoms, approximately 1-2% develop a severe hemorrhagic form of the disease, which can lead to blindness, convulsions, encephalitis, and bleeding, with mortality rates around 50%. The disease has expanded its range in recent years, with outbreaks occurring in the Middle East and Indian Ocean islands, highlighting the growing need for effective vaccines.
Currently, there are registered vaccines for animals, but no licensed vaccines are available for human use. The World Health Organization and the African Centres for Disease Control and Prevention recognize RVF as a priority target disease due to its potential for severe outbreaks and lack of preventive measures for humans.
Strengthening Africa's Vaccine Sovereignty
Dr. Richard Hatchett, CEO of CEPI, emphasized the importance of this research in strengthening Africa's future preparedness and response capabilities. He stated that the project would enhance Africa's vaccine sovereignty and health security by providing a locally produced tool to combat this potentially deadly illness. If clinical trials prove successful, this mRNA vaccine could offer a critical new intervention to protect vulnerable populations and livestock from RVF.